A subanalysis of the phase 3 Study 109 supports switching HIV patients who are virologically suppressed from a tenofovir disoproxil (TDF)-containing regimen to a coformulated tablet containing tenofovir alafenamide (TAF).
In the analysis, individuals who switched from ritonavir- or cobicistat-boosted atazanavir (ATV) plus emtricitabine (FTC)-TDF (Viread, Gilead) to coformulated elvitegravir, cobicistat, FTC and TAF (Genvoya, Gilead) had significantly more reductions in virologic load and